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The integrin α IIb β 3 on resting platelets has a low affinity for its ligands. At sites of vascular injury, exposure of platelets to various soluble agonists (e.g. thrombin and ADP) or subendothelial adhesive proteins (e.g. collagen and von Willebrand factor (VWF)) induces a series of intracellular signaling events (inside-out signaling), leading to activation of the ligand binding function of α IIb β 3 .
Activated α IIb β 3 mediates platelet adhesion and aggregation and plays critical roles in the development of thrombotic diseases such as heart attack and stroke 1-4 . Under flow conditions such as in narrowed artherosclerotic arteries, platelet adhesion to subendothelium is dependent on interaction between the glycoprotein Ib-IX (GPIb-IX) complex and subendothelium-bound VWF 5 . GPIb-IX interaction with the subendothelium-bound VWF initiates platelet adhesion and triggers α IIb β 3 activation, leading to integrin-dependent stable platelet adhesion and aggregation 6-10 . GPIb-IX also binds thrombin and is important in thrombin-induced platelet activation [11] [12] [13] [14] [15] . The signaling mechanism of GPIb-IX-mediated integrin activation is not fully understood but may involve coordination of multiple signaling pathways 9, [16] [17] [18] [19] . We have recently shown that ligand binding to GPIb-IX induces elevation of intracellular cGMP and activation of cGMP-dependent protein kinase (protein kinase G, PKG) 20 , which leads to activation of extracellular signal-regulated kinase (ERK) and activation of α IIb β 3 21 . We have further shown that cGMP-dependent signaling pathway is also important in platelet activation induced by other agonist receptors including protease-activated receptor and collagen receptor 22 .
Mitogen-activated protein kinases (MAPK) are a family of serine/threonine kinases activated by extracellular stimuli including growth factors and hormones. Four distinct subgroups within the MAPK family have been described, including ERK, the c-Jun NH2-terminl kinases (JNK), ERK5/big MAP kinase (BMK1), and p38 group of protein kinases. ERK, JNK, and p38 are activated during platelet For personal use only. on . by guest www.bloodjournal.org From 4 activation 21, 23-25 . ERK can be activated as a result of integrin outside-in signaling in cultured cells 26 , but is apparently negatively regulated by β 3 outside-in signaling in platelets 24 . p38 was initially characterized as an enzyme that was activated in response to endotoxin or stresses such as heat, UV irradiation, osmotic shock, and proinflammatory cytokines 27 . Specific roles of p38 in platelets are unclear. Although a p38 inhibitor, SB203580, was shown to inhibit platelet aggregation induced by low concentrations of certain agonists such as U46619 and collagen 28 , interpretation of these data has been complicated by the report suggesting that SB203580 may directly inhibit cyclooxygenases responsible for TXA 2 synthesis, a process important in platelet aggregation 29 . In this study, we have examined the role of p38 in VWF and thrombin-induced platelet activation using a combination of molecular biology and pharmacology approaches. Our data demonstrate that the p38 pathway is important in VWF and thrombin-induced integrin activation. Our data further show that VWF-or thrombin-induced activation of p38 requires PKG and that PKG-dependent activation of ERK pathway requires p38. These data, together with our recent findings that PKG and ERK are important in integrin activation 20, 21 , delineate a novel signaling pathway in which platelet agonists sequentially activate PKG, p38, and ERK pathways leading to integrin activation.
MATERIALS AND METHODS

Preparation of platelets.
For studies using human blood, approval was obtained from the University of Illinois at Chicago Institutional review board. Informed consent was provided according to the Declaration of Helsinki.
Fresh blood was drawn by venepuncture from healthy volunteers, with one-tenth volume of 3.8% trisodium citrate used as anticoagulant. Platelet-rich plasma (PRP) was obtained by centrifugation at 300 x g for 20 minutes at room temperature. To prepare washed platelets, blood was anti-coagulated with For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 5 ACD (2.5% trisodium citrate, 2% dextrose and 1.5% citric acid) (1.4ml ACD/10ml blood). PRP was further centrifuged at 1200 x g for 15 minutes. Platelets were then washed twice with CGS (sodium chloride 0.12M, trisodium citrate 0.0129 M and glucose 0.03M, pH 6.5) containing 0.1% bovine serum albumin (BSA) and resuspended in the Hepes-buffered Tyrode's solution. They were then allowed to recover to resting state at 25 o C for 1-2 hours as previously described 30 . In experiments for the detection of p38 phosphorylation, platelets were resuspended in Tyrode's buffer to give a concentration of 5 x 10 8 /ml.
Platelet aggregation.
Platelet aggregation was measured using a turbidometric platelet aggregometer at 37 o C with a stirring speed of 1000 rpm. VWF-dependent platelet aggregation was induced by addition of VWF modulators, ristocetin or botrocetin, to PRP. Washed platelets were used in platelet aggregation induced by α-thrombin (Enzyme Research Laboratories) or thrombin receptor activating peptides, SFLLRN or AYPGKF. In some experiments, aspirin (1 mM), RGDS (1 mM) or p38 inhibitors, SB203580 or SB202190, were preincubated with platelets at 37°C for 5 minutes before addition of agonists.
Immunoblot detection of p38 phosphorylation in human platelets.
Washed platelets were incubated with VWF in the presence of botrocetin or ristocetin, or with thrombin (0.05 u/ml) in a platelet aggregometer at 37°C for various lengths of time. Platelets were also incubated with 8-bromo-cGMP (100 µM), 8-bromo-cAMP (100 µM), 8-pCPT-cGMP (100 µM) or SNAP1 (100 µM). In some experiments, platelets were preincubated with KT5823 (5 µM), Rp-pCPTcGMPS (0.2 mM), Rp-Br-PET-cGMPS (0.1 mM), KT 5720 (5 µM) or H89 (50 µM) for 5 minutes prior to adding agonists or PKG activators. Platelets were solubilized in SDS-PAGE sample buffer, containing
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 6 0.2 mM E64 and 2 mM PMSF. Proteins in lysates were separated by SDS-PAGE on a 4-15% polyacrylamide gel and then electro-transferred to PVDF membranes. After blocking in 5% dried skim milk in 0.01M Tris, 0.15 M NaCl, pH7.5 (TBS), PVDF membranes were incubated with the polyclonal anti-p38 antibody or an anti-p38 antibody specifically recognizing the phosphorylation-dependent epitope in the Thr180/Tyr182 site of p38 (New England Biolabs)(1:1000). After 3 washes, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG for 45 minutes.
After further washing, blots were developed using the Enhanced Chemiluminacence kit from PharmaciaAmersham Biotech.
Immunoblot detection of p38 phosphorylation in mouse platelets. and botrocetin (5 µg/ml) in a platelet aggregometer at 37 o C for 30 seconds. Platelets were solubilized in SDS-PAGE sample buffer, containing 0.2 mM E64 and 2 mM PMSF. Phosphorylation of p38 was analyzed as described above.
Generation of a PKG I null (-) (PKG I
-
Expression of p38 dominant negative mutant
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Wild type p38 and a dominant negative mutant of p38 (TGY-AGF)(p38 AF) were generated as described previously 33 . Wild type p38 and p38AF mutant were cloned into the pCDNA3 expression vector with the tagged Flag epitope and were transfected into 123 cells using Lipofectamine plus (BRL).
Expression of p38 and p38AF mutant was assessed by Western blotting with a monoclonal anti-flag M2 antibody (Sigma). Expression levels of GPIb-IX and α IIb β 3 were examined by flow cytometry using a monoclonal antibody against GPIbα, SZ2 (kindly provided by Dr. Changgeng Ruan, Soochow University, Suzhou, China), and a monoclonal antibody againist α IIb β 3 complex, D57 (kindly provided by Dr. Mark Ginsberg, Scripps Research Institute, La Jolla, CA). 
GPIb-IX-mediated integrin activation in reconstituted CHO model.
VWF-induced
Results
GPIb-IX-mediated activation of α IIb β 3 is inhibited by a dominant negative mutant of p38.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org or GPIb-IX, as expression levels of these two receptors in vector-or mutant-transfected cell lines were comparable (Fig. 1C) . Thus, inhibition of the p38 pathway by expression of this dominant negative mutant resulted in inhibition of GPIb-IX-mediated integrin activation.
The role of p38 in integrin activation in human platelets.
To investigate the role of p38 in VWF-induced integrin activation in platelets, we examined the effects of p38 inhibitors, SB203580 and SB202190, on VWF-induced, integrin-dependent platelet aggregation. As expected, addition of ristocetin (or botrocetin (not shown)), which allowed VWF to bind
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From to GPIb-IX, induced α IIb β 3 activation and the first wave of partially integrin-dependent aggregation/agglutination of platelets, leading to the totally integrin-dependent second wave of platelet aggregation (Fig. 2) . Either SB203580 or SB202190 inhibited integrin-dependent platelet aggregation induced by ristocetin ( Fig.2A and 2B) or botrocetin (not shown). It was previously suggested that SB203580 might affect cyclooxygenase activity in platelets 29 . To exclude the possibility that the inhibitory effect of SB203580 is dependent on a possible effect on cyclooxygenases, ristocetin-induced platelet aggregation/agglutination was examined in the presence of a high concentration of aspirin, a cyclooxygenase inhibitor. To verify that aspirin abolished cyclooxygenase function, we showed that aspirin at 0.5 mM or high concentrations completely inhibited arachidonic acid-induced platelet aggregation that is mediated via the cyclooxygenase pathway (Fig. 2C ). As expected, TXA 2 -dependent second wave of platelet aggregation induced by ristocetin was completely abolished in the presence of aspirin (Fig. 2D) . However, the ristocetin-induced first wave of platelet aggregation/agglutination was not affected by aspirin, but was significantly (but partially) inhibited by RGDS peptide even in the presence of aspirin (Fig.2D) , suggesting that VWF-induced integrin activation precedes the second wave of platelet aggregation and is independent of TXA 2 pathway. Addition of SB203580 or SB202190 to the aspirin-treated platelets inhibited ristocetin-induced platelet aggregation in a manner similar to RGDS (Fig. 2D) . These results exclude the possibility that the inhibitory effects of SB203580 or SB202190 on GPIb-mediated integrin activation are caused by their effects on cylooxygenases. Thus, we conclude that the p38 pathway is important in VWF-induced integrin activation in platelets.
To examine whether p38 was required for platelet activation induced by other platelet agonists, washed platelets were preincubated with SB203580 or SB202190, and stimulated with a low dose thrombin (0.05 U/ml). Thrombin-induced platelet activation was inhibited by the p38 inhibitors SB203580 and SB202190 (Fig. 2E) . To exclude the possibility that inhibitory effects of SB203580 or SB202190 resulted from a possible effect on cyclooxgenase 29 , platelets were preincubated with 1 mM aspirin, and stimulated with the same concentration of thrombin. We found that aspirin had no significant inhibitory effect on 0.05 U/ml thrombin-induced platelet aggregation (Fig. 2E) . Thus, the inhibitory effect of SB203580 or SB202190 is unlikely to result from their effects on cyclooxygenase. It is known that low dose thrombin-induced platelet activation requires both GPIb-IX and proteaseactivated receptors (PAR). To investigate whether p38 also plays a role in GPIb-IX-independent platelet activation pathways, we examined the effects of SB203580 on platelet aggregation induced by thrombin receptor activating peptides (TRAPs), SFLLRN (tethered ligand for PAR1) or AYPGKF (ligand for PAR4). SB203580 significantly inhibited platelet aggregation induced by both PAR1 and PAR4 ligands ( Fig. 3A and 3B ). These data indicate that the p38 pathway not only plays an important role in GPIb-IXmediated platelet activation but also in platelet activation-induced by G-protein-coupled receptors.
Activation of p38 in platelets.
If p38 mediates integrin activation signals induced by VWF and thrombin, these agonists would be expected to stimulate p38 activation. It is known that p38 activation is a consequence of p38 phosphorylation at Thr 180 and Tyr 182 by the upstream MAPK kinases (MKK), MKK3/MKK6. Thus, to determine whether p38 is activated following ligand binding to GPIb-IX, we examined phosphorylation of p38 using an anti-p38 antibody recognizing the phosphorylated Thr 180 /Tyr 182 site. Fig. 4A and 4C
show that p38 was rapidly activated in platelets following stimulation by VWF in the presence of ristocetin. VWF-induced p38 phosphorylation peaked after only 1-2 min (variable between different donors), but became significantly reduced within 5 min (Fig. 4A, 4C and 4D ), suggesting that p38
phosphorylation is an early transient event. The time course of p38 phosphorylation induced by VWF (Fig. 4B ) that we previously showed to be transiently activated by VWF 21 . Activation of p38 was also confirmed by an immunoprecipitationkinase assay, using myelin basic protein (MBP) as a p38 substrate (data not shown). To determine whether phosphorylation of p38 is GPIb-IX-dependent, platelets were preincubated with the anti-GPIbα monoclonal antibody, SZ2, before addition of VWF and ristocetin. VWF-induced p38 phosphorylation was inhibited by SZ2 but not by control mouse IgG (Fig. 4E) . Similarly, low dose thrombin also induced p38 phosphorylation (Fig. 4F and 4G) . Furthermore, the integrin inhibitor, RGDS peptide, or the integrin α IIb β 3 blocking antibodies, 2G12 and SZ21, had no inhibitory effect on the phosphorylation of p38 (Fig.4E, 4F and 4G), and RGDS by itself did not induce p38 phosphorylation. Therefore, p38 phosphorylation is unlikely to be caused by integrin outside-in signaling. These data indicate that VWF and thrombin activate p38 in platelets.
Activation of p38 is downstream from PKG in the platelet activation pathway.
We have recently reported that PKG I is an important early stimulatory mediator in the GPIb-IXand PAR-mediated platelet activation pathway 20 . To determine whether PKG is involved in VWFinduced p38 activation, we examined the effect of PKG inhibitors (Rp-pCPT-cGMPS or Rp-Br-PETcGMPS) on GPIb-IX-dependent phosphorylation of p38. PKG inhibitors significantly inhibited VWFinduced p38 phosphorylation, indicating that PKG is important in GPIb-IX-mediated p38 activation (Fig. 5A) . Similarly, low dose thrombin-induced p38 phosphorylation was also inhibited by Rp-Br-PETcGMPS (Fig. 5B) . To exclude the possibility of nonspecific effects of PKG inhibitors, we examined VWF-induced phosphorylation of p38 in PKG I-knockout mouse platelets. VWF significantly enhanced phosphorylation levels of p38 in platelets from wild type mice, but failed to enhance p38
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 13 phosphorylation in PKG I-knockout platelets (Fig. 5C) . Thus, agonist-induced phosphorylation of p38 is downstream from PKG signaling.
To investigate whether activation of PKG is sufficient to stimulate activation of p38, platelets were treated with cGMP analogs, 8-bromo-cGMP or 8-pCPT-cGMP, or the nitric oxide donor, glyco-SNAP1, and then examined for p38 phosphorylation. All these PKG activators induced phosphorylation of p38 (Fig. 6A) . cGMP analog-induced phosphorylation of p38 was inhibited by PKG inhibitors, KT5823 (Fig. 6B) or Rp-pCPT-cGMPS (data not shown). In contrast, PKA inhibitors, KT5720 and H89, had no inhibitory effect on cGMP-induced p38 phosphorylation (Fig. 6B) . Thus, cGMP induces p38 activation by activating PKG. Like VWF and thrombin, cGMP-induced p38 phosphorylation was significantly increased after only 30 seconds, but returned to near background level within 5 min ( Fig.   6C and 6D ). These data indicate that activation of p38 is downstream from the cGMP-PKG pathway during integrin activation in platelets.
The p38 pathway is important in PKG-mediated activation of ERK pathway.
We have recently shown that VWF and thrombin induce activation of the ERK pathway which plays an important role in integrin activation 21 . We have also shown that activation of ERK is downstream from PKG in the GPIb-IX signaling pathway 21 . To investigate the relationship between ERK and p38 pathways during integrin activation, we examined the effects of dominant negative mutants of p38 on VWF-induced phosphorylation of ERK in 123 cells. VWF-mediated phosphorylation of ERK was abolished by expression of p38AF (Fig. 7A) , indicating that p38 is required for VWFinduced activation of the ERK pathway. (Fig. 7C) or by specific p38 inhibitors, SB203580 and SB202190 (Fig. 7D) . Similarly, ERK2 phosphorylation induced by VWF or low dose thrombin in human platelets was inhibited by p38 inhibitors (Fig. 7E and 7F ). However, VWF-induced p38 phosphorylation was not significantly affected by PD98059 (Fig. 7E) . Thus, we conclude that platelet agonists induce a sequential activation of cGMP-PKG, p38 and ERK pathways, leading to integrin activation.
Discussion
Two major findings presented in this study are significant to the signaling mechanisms of platelet integrin activation. First, we have found an important role for p38 MAPK in VWF-and thrombininduced activation of integrin α IIb β 3 . Second, we have delineated a novel signaling pathway in which platelet agonists induce sequential activation of cGMP-PKG, p38, and ERK pathways, leading to the activation of integrin α IIb β 3 . These findings are also of general significance to the understanding of the interaction between intracellular signaling pathways, as we have identified a mechanism by which both p38 and ERK MAPK pathways are activated and a downstream signaling pathway of the important intracellular secondary messenger cGMP.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From Previous studies on the role of p38 in platelet activation have been mainly based on the p38 inhibitor SB203580. This inhibitor inhibited platelet aggregation induced by low concentrations of several platelet agonists, including collagen and thromboxane A2 (TXA2) 28 . However, these results have been interpreted as a consequence of the direct inhibitory effect of SB203580 on TXA2 production by cyclooxygenase 29 . In this study, we show that p38 plays an important role in platelet activation induced by human vWF and low dose thrombin by using a dominant negative mutant of p38 and by using SB203580 under conditions where the reported effect of SB203580 on cyclooxygenase is excluded. Thus, the data presented in this study allow us to conclude that p38 indeed plays an important role in platelet activation. Our data also demonstrate that the effect of SB203580 on platelet activation is unlikely to result from its effect on cyclooxygenase. It is important to note here that cyclooxygenase does not play a significant role in platelet aggregation induced by thrombin at the concentrations used in this study, which is not significantly affected by high concentrations of aspirin (Fig. 2) . Therefore, it is reasonable to use SB203580 as a relatively specific p38 inhibitor to examine the role of p38 in platelet activation induced by agonists such as thrombin.
The effects of SB203580 on VWF-induced platelet activation have also been controversial with studies showing inhibitory effects or showing no effect of this inhibitor on VWF-dependent platelet aggregation 35, 36 . Using dominant negative mutant of p38 as well as p38 inhibitors under conditions that exclude the role of cyclooxygenase, our study provides clear evidence that p38 plays an important role in VWF-induced platelet integrin activation. While the reasons for the difference between different studies are not clear, we noted that if the platelets become partially activated during preparation, VWF stimulation would have minimal stimulatory effects on p38 activation, and the effects of SB203580 on platelet activation would be diminished (not shown). Since we show here that p38 activation is an early While we show that GPIb-IX-induced activation of the p38 pathway is mediated by PKG, we have also previously shown that the cGMP-PKG pathway induces activation of a different MAPK aggregometer stirring at 1000 rpm with buffer, ristocetin alone (0.6 mg/ml), or with ristocetin and VWF (20 µg/ml). A, The platelets were then solubilized and immunoblotted with a rabbit antibody specifically recognizing phosphorylated form of p38 (P-p38), or with a rabbit anti-p38 antibody to indicate comparable loading levels (p38). B, Solublized platelets were also immunoblotted with a rabbit antibody
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From presence or absence of VWF (20 µg/ml) at 37°C for 0.5 min. Platelets from A, B and C were then solubilized, and immunoblotted with an antibody specific for phosphorylated forms of p38 (P-p38) or with an antibody against phosphorylation-independent epitopes of p38 (p38). Note that VWF or thrombin-induced p38 phosphorylation is inhibited by PKG inhibitors and in PKG-knockout platelets. immunoblotting with a rabbit antibody recognizing phosphorylated form of p38 to detect p38 phophorylation (P-p38), and with a rabbit anti-p38 antibody to indicate comparable loading levels (p38).
B.
Platelets were preincubated without (Control) or with DMSO, a PKG inhibitor, KT5823 (5 µM), or PKA inhibitors, KT5720 (5 µM) or H89 (50 µM), at 22°C for 5 min, and then stimulated with 8-pCPTcGMP (100 µM) for 0.5 min. These platelets were solubilized and analyzed by immunoblotting with a rabbit antibody recognizing phosphorylated form of p38 (P-p38), and with a rabbit anti-p38 antibody to indicate comparable loading levels (p38). C and D. Washed human platelets were treated with 8-bromocGMP for 0.5 min or 5 min and then immunoblotted with P-p38 antibody and with p38 antibody as described in (A). Immunoblotting results were scanned and quantitated using NIH Imagine software. 
